<DOC>
	<DOCNO>NCT02320474</DOCNO>
	<brief_summary>This one-year pilot , interventional , prospective , single arm , non-randomized , multicentric ( 3 center ) control study aim evaluate response type 3 choroidal neovascularization treatment Aflibercept follow classic protocol .</brief_summary>
	<brief_title>Efficacy Aflibercept ( Eylea® ) Choroidal Neovascularization ( Type 3 )</brief_title>
	<detailed_description />
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<criteria>Males female age 50 year Patients type 3 choroidal neovascularization assess FA , ICG OCT Exudation SDOCT scan define intraretinal cyst subretinal fluid . Best Corrected Visual Acuity inclusion 24 78 letter ( ETDRS ) Media clarity , pupillary dilation patient cooperation sufficient allow fundus photograph adequate quality Any contraindication report label Aflibercept ( Eylea® ) : Ocular periocular infection , Active intraocular inflammation Hypersensitivity . Any previous history intravitreal injection study eye exudative AMD Any secondary chorioretinal anastomosis due retinal scar fibrosis Any history vitrectomy Media opacities prevent accurate imaging retina ( cataract ) Any retinal disorder possibly associate type 3 CNV ( epiretinal membrane , macular hole ) Confirmed intraocular pressure ≥25 mmHg nonstable glaucoma .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>